Model Early Immunologic Stages of Pediatric Hematological Pre-lupus (PRELUDE)
Model Early Immunologic Stages of Pediatric Hematological Pre-lupus in Order to Prevent SLE in Children.
연구 개요
상태
상세 설명
The development of an autoimmune disease (AID) requires several years. In systemic lupus erythematosus (SLE), anti-nuclear antibodies (ANA) appear several years before the onset of the disease. However, it is difficult to identify the early mechanisms of autoimmunity in humans as most patients' samples are obtained at the time of diagnosis.
We hypothesize that immune thrombocytopenic purpura (ITP) in children provides a unique model for understanding the initial mechanisms leading to autoimmunity. Children with ITP have common immune system dysfunctions leading to the production of anti-platelet antibodies. However, despite this supposedly common dysfunction, the course and degree of loss of tolerance of the immune system are very heterogeneous: the disease is transient in 75 to 80% of cases, and 15 to 20% of children with ITP have ANA and their course is usually persistent or chronic. This subgroup of children with hematological AID, ITP ANA+ meets the criteria for a broader form of AID: pre-lupus. We have recently shown that 16% of these children with pre-lupus / ITP-ANA+ progressed to complete SLE within a median of 3.8 years. Why do some children have transient or persistent ITP? limited or systemic ITP? We aim to describe the shared and/or unique immunological pathways involved at diagnosis in children with ITP ANA- (transient or persistent), with ITP ANA+ (pre-lupus condition, transient or persistent), and in patients with SLE (persistent by definition) In this exploratory, prospective, bi-centric cohort study, we will include 70 children with ITP and 20 children with SLE newly diagnosed, over 36 months with a 3-month follow-up for children with ITP-ANA- and SLE and a 48-month follow-up for children with ITP-ANA+. ANA positivity will be defined by a titer ≥ 1/160. Blood samples will be collected at inclusion and at 3 months (bio-collection), and further each 6 months for children with ITP-ANA+. ITP status will be defined at 3 months: transient or persistent. We will analyze the signaling pathways (B and T lymphocytes, cytokines, disruption of tolerance and inactivation of X) involved in these different pathophysiological distinct subgroups
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Nathalie ALADJIDI, MD
- 이메일: nathalie.aladjidi@chu-bordeaux.fr
연구 연락처 백업
- 이름: Jérôme GRANEL, MD
- 전화번호: +33 5 57 82 02 55
- 이메일: jerome.granel@chu-bordeaux.fr
연구 장소
-
-
-
Bordeaux, 프랑스, 33076
- Chu de Bordeaux- Groupe Hospitalier Pellegrin - Hôpital des Enfants
-
연락하다:
- Jérôme GRANEL, MD
- 전화번호: +33 5 57 82 02 55
- 이메일: jerome.granel@chu-bordeaux.fr
-
Toulouse, 프랑스, 31026
- CHU Toulouse - Hôpital des Enfants
-
연락하다:
- Marlène PASQUET, PROF
- 전화번호: +33 5 34 55 86 43
- 이메일: pasquet.m@chu-toulouse.fr
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
건강한 자원 봉사자를 받아들입니다
설명
Inclusion criteria:
For patients :
- Child or adolescent with newly diagnosed ITP or SLE according to the specific definitions of ITP or SLE, prior to any treatment,
- Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg.
- Written consent from parents or guardians,
- Patient affiliated to a social security scheme.
For controls :
- Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg.
- Follow-up in the day hospital at the Bordeaux University Hospital, for a condition that does not affect the immune system
- Matched on age,
- Written consent from parents or guardians,
- Patient affiliated to a social security scheme
Exclusion criteria:
For patients :
- ITP secondary to a known cause: previous or concomitant immune deficiency, bone marrow or organ transplantation, other autoimmune disease, Evans syndrome (autoimmune hemolytic anemia or autoimmune neutropenia present at ITP diagnosis) or cancer with immunosuppressive therapy.
- Treatment with immunomodulation or immunosuppressants (including immunoglobulins, corticoids, hydroxychloroquine), started prior to inclusion (day of sampling).
- Pregnant women, women in labour and breastfeeding women
For controls :
- Suffering from an immunological disease,
- Infection within fifteen days prior to inclusion,
- Immunomodulatory therapy.
- Pregnant women, women in labour and breastfeeding women
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: 통제 수단
|
Blood sampling is a routine biological procedure performed under the same conditions as during a follow-up consultation.
Monitoring for Systemic Lupus Erythematosus according to SLICC 2012 classification criteria
|
|
다른: ITP-ANA-
|
Blood sampling is a routine biological procedure performed under the same conditions as during a follow-up consultation.
Monitoring for Systemic Lupus Erythematosus according to SLICC 2012 classification criteria
|
|
다른: ITP-ANA+
|
Blood sampling is a routine biological procedure performed under the same conditions as during a follow-up consultation.
Monitoring for Systemic Lupus Erythematosus according to SLICC 2012 classification criteria
|
|
다른: SLE
|
Blood sampling is a routine biological procedure performed under the same conditions as during a follow-up consultation.
Monitoring for Systemic Lupus Erythematosus according to SLICC 2012 classification criteria
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Characterisation of B and T lymphocyte populations
기간: Baseline, Month 3 visit.
|
Characterisation of B and T lymphocyte populations through the study of surface markers and intracellular factors.
This panel will, in particular, enable the identification of effector B cells such as plasma blasts, subsets of auto-reactive 'double-negative' (DN) B cells, regulatory B cells, and follicular T helper (Tfh) and peripheral extra-follicular T helper (Tph) cells.
Each population will be compared between the patients and the control group.
|
Baseline, Month 3 visit.
|
|
Plasma markers
기간: Baseline, Month 3 visit.
|
Soluble cytokines and factors regulating B-cell survival (BAFF, TACI, IL-6, IL-12p70, IFN-γ, IFN-β, TGF-β, and the IFN-regulated chemokine CXCL10) will be quantified in plasma using a customised multiplex Luminex assay.
Interferon alpha levels will be specifically measured using ultra-sensitive SIMOA (Single Molecule Array) technology.
|
Baseline, Month 3 visit.
|
|
Plasma markers
기간: Baseline, Month 3 visit.
|
Circulating plasma autoantigens - soluble P-selectin and CD40L derived from platelet activation - will be measured by ELISA.
The levels of circulating and mitochondrial DNA will be measured by quantitative RT-PCR in collaboration with V. Sisirak (DR CNRS, Immunoconcept).
The overall activity of plasma DNases will be determined by an in vitro DNA degradation assay.
|
Baseline, Month 3 visit.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Single-cell transcriptomic analysis
기간: Baseline, Month 3 visit , Month 6 visit , Month 12 visit, Month 18 visit, Month 24 visit , Month 30 visit, Month 36 visit, Month 42 visit and Month 48 visit.
|
Using single-cell RNA sequencing, a single-cell transcriptomic analysis, we will be able to quantify and analyse the transcriptomes of lymphocytes B This will enable us to characterise heterogeneous cell populations, as well as to reconstruct cell development pathways and model transcriptomic dynamics. This technique will enable the modelling of signalling pathways involving B lymphocytes in the subgroup of ITP patients with positive AAN titres, and the development of an algorithm and a mathematical model of the progression of these cellular and molecular markers |
Baseline, Month 3 visit , Month 6 visit , Month 12 visit, Month 18 visit, Month 24 visit , Month 30 visit, Month 36 visit, Month 42 visit and Month 48 visit.
|
|
Single cell epigenetic analysis
기간: Baseline, Month 3 visit , Month 6 visit , Month 12 visit, Month 18 visit, Month 24 visit , Month 30 visit, Month 36 visit, Month 42 visit and Month 48 visit.
|
Using single-cell ATAC sequencing, we will be able to analyse the regions of DNA accessible to the transcription machinery. This will enable us to identify regulatory programmes such as signalling pathways. The analysis will also reveal heterogeneity amongst B-cell subpopulations, which may respond differently to signals. This will provide insight into the epigenetic status of genes, or at least into which factors regulate this signalling pathway and how the cell adjusts its response depending on its situation or stage of maturity, or on the signal itself. |
Baseline, Month 3 visit , Month 6 visit , Month 12 visit, Month 18 visit, Month 24 visit , Month 30 visit, Month 36 visit, Month 42 visit and Month 48 visit.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Jérôme GRANEL, MD, University Hospital, Bordeaux
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CHUBX 2025/052
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
전신성 홍반성 루푸스(SLE)에 대한 임상 시험
-
Union Hospital, Tongji Medical College, Huazhong...아직 모집하지 않음전신 홍반성 루푸스(Systemic Lupus Erythematosus, SLE)중국
-
Istanbul Galata UniversityThe Scientific and Technological Research Council of Turkey아직 모집하지 않음전신 홍반성 루푸스(Systemic Lupus Erythematosus, SLE)터키 (Türkiye)
-
Tongji Hospital아직 모집하지 않음전신 홍반성 루푸스(Systemic Lupus Erythematosus, SLE)중국
-
University of California, San Francisco완전한
-
Union Hospital, Tongji Medical College, Huazhong...Everest Medicines (China) Co.,Ltd.모병경피증 | 전신 홍반성 루푸스(Systemic Lupus Erythematosus, SLE) | 중증근무력증(MG)중국